- Home
- CVKD
as 04-17-2025 4:00pm EST
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
| Founded: | 2022 | Country: | United States |
| Employees: | N/A | City: | PONTE VEDRA |
| Market Cap: | 31.5M | IPO Year: | 2023 |
| Target Price: | $32.00 | AVG Volume (30 days): | 22.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.73 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.70 - $22.90 | Next Earning Date: | 05-08-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cadrenal Therapeutics Inc. News
CVKD Breaking Stock News: Dive into CVKD Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 days ago
Is Cadrenal Therapeutics (NASDAQ:CVKD) In A Good Position To Deliver On Growth Plans?
Business Wire
15 days ago
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
Zacks Small Cap Research
18 days ago
CVKD: Preparing for Phase 3 Trial of Tecarfarin…
Business Wire
a month ago
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
Zacks Small Cap Research
a month ago
CVKD: Collaborating with Abbott for Pivotal Phase 3 Trial…
Medical Device Network
a month ago
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin
MT Newswires
a month ago
Cadrenal Therapeutics to Collaborate With Abbott on Trial of Heart Device Drug
Business Wire
a month ago
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
Compare CVKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVKD Cadrenal Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.